What are people thoughts on $GERN? Geron's primary asset is Imetelstat, which is is in two critical trials right now: IMbark (myelofibrosis) and IMerge (low-risk MDS). Geron is scheduled to announce the results of the second phase of its testing in the coming two weeks. Geron is partnered with Janssen, a subsidiary of Johnson & Johnson, in the R&D of these trials. Janssen will make its continuation decision on these two trials which will likely make or break Geron for the time being. Im thinking that Geron looks like a prime candidate for a buyout from a larger company, possibly J&J or a company like $GILD which has tons of cash stored up. $GILD has been rumored to be interested in taking over a small cap pharma company with a drug in phase three of development that treats a disease/disorder that currently doesn't great have treatment alternatives. With a market cap of $337 million, $GERN seems like a prime candidate if they announce positive phase two results.
[link] [comments]
March 21, 2017 at 05:02AM
http://ift.tt/2mmNcbe
from /u/Sheffy077
http://ift.tt/2mmNcbe
No comments:
Post a Comment